Merck KGaA, Darmstadt, Germany Agrees to Acquire Bio-Techne for $11.3 Billion

Details

The acquisition, which is expected to close by late 2026 or early 2027, will be funded through a combination of existing cash and new debt. The deal represents a 36% premium to Bio-Techne's one-month volume weighted average trading price and is expected to be immediately accretive to Merck KGaA, Darmstadt, Germany's EBITDA pre margin post-closing and EPS pre accretive by year 3 after closing. The transaction will strengthen Merck KGaA, Darmstadt, Germany's position in high-growth life sciences markets and add complementary strengths across research, bioprocessing, and advanced therapeutics.

Items reported

About Bio-Techne Corporation

Bio-Techne Corporation is a leading developer and manufacturer of high-quality biological products and solutions for the research and clinical diagnostic markets. The company specializes in providing an extensive range of biotechnological tools that support the advancement of life sciences. Key offerings include proteins, antibodies, assay kits, and laboratory services critical for scientific research and drug development. Bio-Techne operates across diverse sectors such as biotechnology, pharmaceuticals, academic research, and healthcare, supplying innovative solutions that facilitate groundbreaking research and therapeutic discoveries. Its products are essential in advancing modern biology and medicine, contributing to significant developments in areas like cancer research, immunology, and cell biology. Bio-Techne’s commitment to innovation and quality makes it a pivotal player in the biotechnology industry, elevating scientific discovery and fostering advancements in personalized medicine and diagnostics. With a strong global presence, Bio-Techne continues to impact the global life sciences landscape profoundly, upholding a legacy of excellence and reliability in the biotechnological sector.